Journal of Clinical Oncology · 2004 · 11 citations · 0 references
PharmacyPharmacologyPharmacotherapyCancer PharmacologyChemotherapyPharmacokinetics Of Anticancer AgentsChemotherapy Toxicity ManagementColorectal CancerDose Adjustment In OncologyGastrointestinal Cancer PharmacotherapyToxicity ManagementTyrosine Kinase InhibitorsChemotherapy-induced Gastrointestinal ToxicityErlotinib TherapyFebrile Neutropenia De-escalationFebrile Neutropenia TreatmentIrinotecan-based TherapyMaximum Tolerated EffectTyrosine Kinase Inhibitor Therapy
3572 Background: Gefitinib (Iressa, ZD1839) is an orally active epidermal growth factor receptor tyrosine kinase inhibitor that potentiates the effects of irinotecan in preclinical models. This study aims to establish the maximum tolerated dose (MTD) of administering gefitinib in combination with irinotecan and to assess safety and efficacy. Methods: Patients with advanced CRC progressing on or within 12 weeks of fluoropyrimidine-based chemotherapy were recruited. In cohort 1, patients were treated with irinotecan 250mg/m2 once every 3 weeks and gefitinib 250mg daily starting on day 1. Two dose limiting toxicities (DLTs), prolonged grade 4 neutropenia and grade 3 diarrhoea with neutropenic sepsis, were seen at this starting level. Thus two lower dose levels were explored in cohort 2 (irinotecan 200mg/m2 day 1) and cohort 3 (irinotecan 225mg/m2 day 1) both given with gefitinib 250mg daily starting on day 3. Pharmacokinetic (PK) studies were instigated in cohorts 2 and 3. Results: Eighteen patients were treated with ≥1 cycle in total. Baseline demographics and maximum grade toxicity in any cycle are shown in the table. One patient in cohort 2 developed grade 4 vomiting before starting gefitinib and was not considered a DLT. Another patient in cohort 3 developed febrile neutropenia in cycle 2. So far, 4 patients had disease stabilization of ≥12 weeks, all of whom developed a skin rash during treatment, with 1 patient having stable disease for 17 months. Conclusions: Dose limiting toxicities, especially neutropenia, occurred at an unexpectedly low dose of irinotecan in combination with gefitinib and on-going PK analysis may provide further insight. Irinotecan 225mg/m2 and gefitinib 250mg daily is recommended as the MTD and this dose level is being expanded in a phase II study. 'Iressa' is a trademark of the AstraZeneca group of companies Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca AstraZeneca AstraZeneca AstraZeneca (UK)